The GLasses Against transmission of SARS-CoV-2 in the communitY (GLASSY) trial: A pragmatic randomized trial (study protocol)
View ORCID ProfileAtle Fretheim, View ORCID ProfileLars G. Hemkens, View ORCID ProfileArnfinn Helleve, View ORCID ProfileIngeborg Hess Elgersma, View ORCID ProfilePetter Elstrøm, View ORCID ProfileOliver Kacelnik
doi: https://doi.org/10.1101/2022.02.04.22270120
Atle Fretheim
1Centre for Epidemic Interventions Research, Norwegian Institute of Public Health, Oslo, Norway
2Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway
Roles: (project lead)
Lars G. Hemkens
3Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland
4Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, USA
5Meta-Research Innovation Center Berlin (METRIC-B), Berlin Institute of Health, Berlin, Germany
Arnfinn Helleve
6Centre for Evaluation of Public Health Interventions, Norwegian Institute of Public Health, Oslo, Norway
Ingeborg Hess Elgersma
1Centre for Epidemic Interventions Research, Norwegian Institute of Public Health, Oslo, Norway
Petter Elstrøm
1Centre for Epidemic Interventions Research, Norwegian Institute of Public Health, Oslo, Norway
7Division for Infection Control, Norwegian Institute of Public Health, Oslo. Norway
Oliver Kacelnik
1Centre for Epidemic Interventions Research, Norwegian Institute of Public Health, Oslo, Norway
7Division for Infection Control, Norwegian Institute of Public Health, Oslo. Norway
Data Availability
We intend to make the dataset publicly available after at has been fully anonymised.
Posted February 06, 2022.
The GLasses Against transmission of SARS-CoV-2 in the communitY (GLASSY) trial: A pragmatic randomized trial (study protocol)
Atle Fretheim, Lars G. Hemkens, Arnfinn Helleve, Ingeborg Hess Elgersma, Petter Elstrøm, Oliver Kacelnik
medRxiv 2022.02.04.22270120; doi: https://doi.org/10.1101/2022.02.04.22270120
The GLasses Against transmission of SARS-CoV-2 in the communitY (GLASSY) trial: A pragmatic randomized trial (study protocol)
Atle Fretheim, Lars G. Hemkens, Arnfinn Helleve, Ingeborg Hess Elgersma, Petter Elstrøm, Oliver Kacelnik
medRxiv 2022.02.04.22270120; doi: https://doi.org/10.1101/2022.02.04.22270120
Subject Area
Subject Areas
- Addiction Medicine (395)
- Allergy and Immunology (707)
- Anesthesia (198)
- Cardiovascular Medicine (2899)
- Dermatology (249)
- Emergency Medicine (435)
- Epidemiology (12660)
- Forensic Medicine (10)
- Gastroenterology (816)
- Genetic and Genomic Medicine (4514)
- Geriatric Medicine (411)
- Health Economics (721)
- Health Informatics (2885)
- Health Policy (1061)
- Hematology (381)
- HIV/AIDS (916)
- Medical Education (419)
- Medical Ethics (115)
- Nephrology (466)
- Neurology (4279)
- Nursing (231)
- Nutrition (629)
- Oncology (2244)
- Ophthalmology (638)
- Orthopedics (256)
- Otolaryngology (323)
- Pain Medicine (274)
- Palliative Medicine (83)
- Pathology (492)
- Pediatrics (1187)
- Primary Care Research (491)
- Public and Global Health (6861)
- Radiology and Imaging (1508)
- Respiratory Medicine (912)
- Rheumatology (432)
- Sports Medicine (379)
- Surgery (478)
- Toxicology (60)
- Transplantation (206)
- Urology (177)